Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Diabetic Macular Edema Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02933905
• Other study ID #: OFT-RAN-2013-01
• Status: Completed
• Phase: N/A
• First received: October 12, 2016
• Last updated: October 14, 2016
• Start date: January 2014
• Est. completion date: June 2016

Study information

• Verified date: October 2016
• Source: Fundació Institut Germans Trias i Pujol
• Contact: n/a
• Is FDA regulated: No
• Health authority: Institut Català de la Salut. Barcelona, Spain:
• Study type: Observational

Clinical Trial Summary

Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: June 2016
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• diabetic macular edema treatable with antiangiogenic drugs

Exclusion Criteria:

• age under 18

• cardiovascular events during the last year

• previous vitrectomy

• previous macular edema treatment during the last 4 months

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Anti-VEGF Treatment
• Diabetic Macular Edema
• Edema
• Macular Edema
• Vitreomacular Interface

Intervention

Drug:
• Intravitreal Ranibizumab injection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Institut Germans Trias i Pujol

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in best-corrected visual acuity		One year	No
Secondary	Change in central macular thickness		One year	No
Secondary	Number of ranibizumab injections		One year	No